Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
June 30, 2025 - … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated … to treat AMR, PMN or IgAN, our commercial business and pipeline programs; capital allocation and investment … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated …
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
June 27, 2025 - … of SMA; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and … of SMA; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and … of SMA; the potential of our commercial business and pipeline programs, including SPINRAZA; and risks and …
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
June 25, 2025 - … of SMA; the potential of our commercial business and pipeline programs, including BIIB115; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … of SMA; the potential of our commercial business and pipeline programs, including BIIB115; and risks and …
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
June 18, 2025 - … ataxia; the potential of Biogen’s commercial business and pipeline programs, including Friedreich’s ataxia; and risks … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … ataxia; the potential of Biogen’s commercial business and pipeline programs, including Friedreich’s ataxia; and risks …
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
June 12, 2025 - … development, changes in the prospects for products in the pipeline or under development by UCB, effects of future … product candidates will be discovered or identified in the pipeline, or that new indications for existing products will … of, and expectations for, our commercial business and pipeline programs; capital allocation and investment …
Wed, 06/11/2025 - 10:00 - … Biogen Thematic Pipeline Seminar: Rare Kidney Disease Biogen Thematic Pipeline Seminar: Rare Kidney Disease Event Type Conference … Listen to webcast Supporting Materials Biogen Thematic Pipeline Seminar: Rare Kidney Disease 1.7 MB Jun 11, 2025 … Biogen Thematic Pipeline Seminar: Rare Kidney Disease …
Biogen Thematic Pipeline Seminar: Rare Kidney Disease
Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases
June 11, 2025 - … products, and advance an innovative and compelling pipeline,” said Christopher A. Viehbacher, President and … first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated … of, and expectations for, our commercial business and pipeline programs; capital allocation and investment …
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
May 27, 2025 - … reach of RNAi-based medicines. The company is building a pipeline of innovative RNAi therapeutics to make a … of, and expectations for, our commercial business and pipeline programs, including in connection with RNAi-based … actions to improve risk profile and productivity of R&D pipeline, collaborations, and business development …
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
April 15, 2025 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
